Browse SMARCA4

Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Colocalizes with long non-coding RNA Evf2 in nuclear RNA clouds.
Domain PF07533 BRK domain
PF00439 Bromodomain
PF00271 Helicase conserved C-terminal domain
PF07529 HSA
PF08880 QLQ
PF14619 Snf2-ATP coupling
PF00176 SNF2 family N-terminal domain
Function

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating the calcium-dependent release of a repressor complex and the recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by SMARCA4-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves the release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development, a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues (By similarity). Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1. Binds via DLX1 to enhancers located in the intergenic region between DLX5 and DLX6 and this binding is stabilized by the long non-coding RNA (lncRNA) Evf2 (By similarity). Binds to RNA in a promiscuous manner (By similarity). Binding to RNAs including lncRNA Evf2 leads to inhibition of SMARCA4 ATPase and chromatin remodeling activities (By similarity).

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001558 regulation of cell growth
GO:0001654 eye development
GO:0001678 cellular glucose homeostasis
GO:0003407 neural retina development
GO:0006333 chromatin assembly or disassembly
GO:0006337 nucleosome disassembly
GO:0006338 chromatin remodeling
GO:0006356 regulation of transcription from RNA polymerase I promoter
GO:0006360 transcription from RNA polymerase I promoter
GO:0007067 mitotic nuclear division
GO:0007068 negative regulation of transcription during mitosis
GO:0007070 negative regulation of transcription from RNA polymerase II promoter during mitosis
GO:0007346 regulation of mitotic cell cycle
GO:0007423 sensory organ development
GO:0009303 rRNA transcription
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009755 hormone-mediated signaling pathway
GO:0009756 carbohydrate mediated signaling
GO:0009757 hexose mediated signaling
GO:0010182 sugar mediated signaling pathway
GO:0010255 glucose mediated signaling pathway
GO:0010948 negative regulation of cell cycle process
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030308 negative regulation of cell growth
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030521 androgen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0031498 chromatin disassembly
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032984 macromolecular complex disassembly
GO:0032986 protein-DNA complex disassembly
GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway
GO:0033144 negative regulation of intracellular steroid hormone receptor signaling pathway
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0034728 nucleosome organization
GO:0035821 modification of morphology or physiology of other organism
GO:0042593 glucose homeostasis
GO:0042790 transcription of nuclear large rRNA transcript from RNA polymerase I promoter
GO:0043010 camera-type eye development
GO:0043044 ATP-dependent chromatin remodeling
GO:0043241 protein complex disassembly
GO:0043401 steroid hormone mediated signaling pathway
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043923 positive regulation by host of viral transcription
GO:0044033 multi-organism metabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045896 regulation of transcription during mitosis
GO:0045926 negative regulation of growth
GO:0045930 negative regulation of mitotic cell cycle
GO:0045943 positive regulation of transcription from RNA polymerase I promoter
GO:0046021 regulation of transcription from RNA polymerase II promoter, mitotic
GO:0046782 regulation of viral transcription
GO:0048524 positive regulation of viral process
GO:0048545 response to steroid hormone
GO:0050434 positive regulation of viral transcription
GO:0050792 regulation of viral process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0060041 retina development in camera-type eye
GO:0060765 regulation of androgen receptor signaling pathway
GO:0060766 negative regulation of androgen receptor signaling pathway
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071824 protein-DNA complex subunit organization
GO:0098781 ncRNA transcription
GO:0198738 cell-cell signaling by wnt
GO:1901836 regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter
GO:1901838 positive regulation of transcription of nuclear large rRNA transcript from RNA polymerase I promoter
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902659 regulation of glucose mediated signaling pathway
GO:1902661 positive regulation of glucose mediated signaling pathway
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:1904837 beta-catenin-TCF complex assembly
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001013 RNA polymerase I regulatory region DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001104 RNA polymerase II transcription cofactor activity
GO:0001105 RNA polymerase II transcription coactivator activity
GO:0001158 enhancer sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0001163 RNA polymerase I regulatory region sequence-specific DNA binding
GO:0001164 RNA polymerase I CORE element sequence-specific DNA binding
GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0002039 p53 binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0003714 transcription corepressor activity
GO:0004386 helicase activity
GO:0008094 DNA-dependent ATPase activity
GO:0008134 transcription factor binding
GO:0016887 ATPase activity
GO:0030957 Tat protein binding
GO:0031490 chromatin DNA binding
GO:0031491 nucleosome binding
GO:0031492 nucleosomal DNA binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0035326 enhancer binding
GO:0042393 histone binding
GO:0042623 ATPase activity, coupled
GO:0043566 structure-specific DNA binding
GO:0047485 protein N-terminus binding
GO:0050681 androgen receptor binding
GO:0051427 hormone receptor binding
GO:0070182 DNA polymerase binding
GO:0070577 lysine-acetylated histone binding
GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0016514 SWI/SNF complex
GO:0044454 nuclear chromosome part
GO:0070603 SWI/SNF superfamily-type complex
GO:0071564 npBAF complex
GO:0071565 nBAF complex
GO:0090544 BAF-type complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-201722: Formation of the beta-catenin
R-HSA-168256: Immune System
R-HSA-1266695: Interleukin-7 signaling
R-HSA-3214858: RMTs methylate histone arginines
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SMARCA4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SMARCA4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.66; FDR: 0.012 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 4.26; FDR: 0.039 Sensitive to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SMARCA4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0260.925
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1340.955
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0480.979
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3080.353
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0650.981
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6170.86
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.060.877
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0930.96
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2550.899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2320.884
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8610.703
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1240.0695
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SMARCA4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.312.520.80.312
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475014.335.70.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SMARCA4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SMARCA4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SMARCA4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SMARCA4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SMARCA4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SMARCA4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSMARCA4
NameSWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
Aliases hSNF2b; BRG1; SNF2-BETA; FLJ39786; SNF2-like 4; sucrose nonfermenting-like 4; mitotic growth and transcripti ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SMARCA4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.